Nicholas Ashton
Neuroscientist in Dementia / Banner Health 🇺🇸/ University of Gothenburg 🇸🇪
Articles
-
2 weeks ago |
alz-journals.onlinelibrary.wiley.com | Ilaria Pola |Nicholas Ashton |Wagner S. Brum |Nesrine Rahmouni
1 BACKGROUND Alzheimer's disease (AD) is a progressive pathophysiological process characterized by the accumulation of amyloid-β (Aβ) and tau proteins, ultimately leading to neurodegeneration and cognitive decline.1, 2 In this context, neuroinflammation has been suggested as a significant contributor to AD progression.3, 4 Studies in mouse models of Aβ and tau suggest that microglial reactivity may accelerate Aβ plaque deposition and tau spreading, with immune-related alterations observed in...
-
2 months ago |
alz-journals.onlinelibrary.wiley.com | Yara Yakoub |Fernando Gonzalez-Ortiz |Nicholas Ashton |Christine Déry
1 BACKGROUND The core pathological hallmarks that define Alzheimer's disease (AD) are plaque-forming aggregates of amyloid beta (Aβ) and neurofibrillary tangles of hyper-phosphorylated tau (p-tau).
-
Jan 6, 2025 |
thelancet.com | Nicholas Ashton |SUN CITY
In 2014, when eBioMedicine launched its first issue, in vivo biomarkers to detect the hallmarks of Alzheimer’s disease (AD) were entirely restricted to position emission tomography (PET) and cerebrospinal fluid (CSF). There was certainly limited enthusiasm that a comparable determination about AD pathology or neurodegeneration could be made from an easily accessible biofluid such as blood.
-
Dec 30, 2024 |
alzres.biomedcentral.com | Maxime Van Egroo |Elise Beckers |Nicholas Ashton |Kaj Blennow |Henrik Zetterberg
ReferencesVan Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, et al. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease. Sleep. 2019;42:1–13. Google Scholar Rigat L, Ouk K, Kramer A, Priller J. Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer’s disease. Acta Physiol. 2023;238:1–13. Google Scholar Winer JR, Morehouse A, Fenton L, Harrison TM, Ayangma L, Reed M, et al.
-
Dec 23, 2024 |
alzres.biomedcentral.com | Georgette Argiris |Muge Akinci |Cleofé Peña-Gómez |Eleni Palpatzis |Marina García-Prat |Mahnaz Shekari | +8 more
ReferencesJack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Article PubMed Google Scholar Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 3K
- DMs Open
- Yes
Our comments on the new #blood tests for #Alzheimers #disease which are increasingly improving and becoming applicable to clinical use. We should use them but use them in the correct way. https://t.co/fmxJGPu2Zb
RT @M_SuarezCalvet: 📢Our latest study, now published in @NatureMedicine , explores the potential of blood biomarkers on an automated platfo…
RT @biofinder_study: New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’…
